Academic Journal
A Three-Dimensional Xeno-Free Culture Condition for Wharton's Jelly-Mesenchymal Stem Cells: The Pros and Cons.
| Title: | A Three-Dimensional Xeno-Free Culture Condition for Wharton's Jelly-Mesenchymal Stem Cells: The Pros and Cons. |
|---|---|
| Authors: | Koh B; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Ming Medical Sdn Bhd, D3-3 (2nd Floor), Block D3 Dana 1 Commercial Centre, Jalan PJU 1a/46, Petaling Jaya 47301, Malaysia., Sulaiman N; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Fauzi MB; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Law JX; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Ng MH; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Yuan TL; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Azurah AGN; Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Mohd Yunus MH; Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Idrus RBH; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia., Yazid MD; Centre for Tissue Engineering & Regenerative Medicine, Faculty of Medicine, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia.; Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2023 Feb 13; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 13. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| MeSH Terms: | Mesenchymal Stem Cells* , Wharton Jelly*/cytology , Wharton Jelly*/metabolism , Cell Culture Techniques, Three Dimensional*/methods, Humans ; Cell Culture Techniques/methods ; Cell Differentiation ; Cell Proliferation ; Cells, Cultured ; Culture Media |
| Abstract: | Xeno-free three-dimensional cultures are gaining attention for mesenchymal stem cell (MSCs) expansion in clinical applications. We investigated the potential of xeno-free serum alternatives, human serum and human platelet lysate, to replace the current conventional use of foetal bovine serum for subsequent MSCs microcarrier cultures. In this study, Wharton's Jelly MSCs were cultured in nine different media combinations to identify the best xeno-free culture media for MSCs culture. Cell proliferation and viability were identified, and the cultured MSCs were characterised in accordance with the minimal criteria for defining multipotent mesenchymal stromal cells by the International Society for Cellular Therapy (ISCT). The selected culture media was then used in the microcarrier culture of MSCs to determine the potential of a three-dimensional culture system in the expansion of MSCs for future clinical applications, and to identify the immunomodulatory potential of cultured MSCs. Low Glucose DMEM (LG) + Human Platelet (HPL) lysate media appeared to be good candidates for replacing conventional MSCs culture media in our monolayer culture system. MSCs cultured in LG-HPL achieved high cell yield, with characteristics that remained as described by ISCT, although the overall mitochondrial activity of the cells was lower than the control and the subsequent effects remained unknown. MSC microcarrier culture, on the other hand, showed comparable cell characteristics with monolayer culture, yet had stagnated cell proliferation, which is potentially due to the inactivation of FAK. Nonetheless, both the MSCs monolayer culture and the microcarrier culture showed high suppressive activity on TNF-α, and only the MSC microcarrier culture has a better suppression of IL-1 secretion. In conclusion, LG-HPL was identified as a good xeno-free media for WJMSCs culture, and although further mechanistic research is needed, the results show that the xeno-free three-dimensional culture maintained MSC characteristics and improved immunomodulatory activities, suggesting the potential of translating the monolayer culture into this culture system in MSC expansion for future clinical application. Competing Interests: The authors declare that they have no conflicts of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. |
| References: | Biomaterials. 2016 Jan;76:371-87. (PMID: 26561934) J Inorg Biochem. 2022 Feb;227:111682. (PMID: 34902763) Am J Hum Genet. 2002 Jul;71(1):198-203. (PMID: 12032915) Curr Res Transl Med. 2020 Jan;68(1):5-16. (PMID: 31543433) Stem Cells. 2015 Jul;33(7):2158-68. (PMID: 24964196) Stem Cell Res Ther. 2015 Apr 13;6:55. (PMID: 25884704) Biotechnol Bioeng. 2018 Jul;115(7):1717-1728. (PMID: 29578573) In Vitro. 1982 Jun;18(6):576-84. (PMID: 7118138) Appl Intell (Dordr). 2022;52(9):9676-9700. (PMID: 35035091) Cell Biochem Funct. 2020 Mar;38(2):130-140. (PMID: 31957071) Med (N Y). 2020 Dec 18;1(1):90-102. (PMID: 33294881) Stem Cell Res Ther. 2020 Sep 18;11(1):404. (PMID: 32948252) Rev Recent Clin Trials. 2018;13(3):210-214. (PMID: 29542422) Stem Cells Transl Med. 2021 May;10(5):660-673. (PMID: 33400390) N Engl J Med. 2006 Aug 10;355(6):581-92. (PMID: 16899778) Br J Cancer. 2020 Sep;123(7):1154-1163. (PMID: 32632148) Cell Biol Int. 2009 Jun;33(6):665-74. (PMID: 19376254) Sci Rep. 2020 Jun 22;10(1):10085. (PMID: 32572149) Clin Chim Acta. 2019 Sep;496:35-44. (PMID: 31229566) J Biol Regul Homeost Agents. 2019 Feb 4;34(1):9-14. (PMID: 32013309) Int J Stem Cells. 2021 Feb 28;14(1):94-102. (PMID: 33377452) Nutrients. 2021 Jul 22;13(8):. (PMID: 34444658) Biotechnol Lett. 2011 Nov;33(11):2325-35. (PMID: 21769648) Stem Cell Rev Rep. 2015 Jun;11(3):423-41. (PMID: 25287760) Front Immunol. 2019 Jun 07;10:1197. (PMID: 31231372) Sci Rep. 2018 Aug 20;8(1):12439. (PMID: 30127445) Clin Immunol. 2020 Oct;219:108538. (PMID: 32681980) Cytotherapy. 2014 Feb;16(2):170-80. (PMID: 24438898) Physiol Res. 2019 Nov 30;68(Suppl 2):S131-S138. (PMID: 31842576) Stem Cells. 2007 Jun;25(6):1431-8. (PMID: 17347495) Immunity. 2019 Apr 16;50(4):778-795. (PMID: 30995499) Int J Mol Sci. 2020 Apr 13;21(8):. (PMID: 32294921) Cytokine Growth Factor Rev. 2022 Dec;68:25-36. (PMID: 35843774) Transfus Med Hemother. 2013 Oct;40(5):326-35. (PMID: 24273486) Platelets. 2022 Jan 2;33(1):98-109. (PMID: 33393414) Stem Cell Res Ther. 2016 Dec 9;7(1):187. (PMID: 27938398) Bull Exp Biol Med. 2013 Nov;156(1):146-51. (PMID: 24319712) PLoS One. 2013 Jul 11;8(7):e68984. (PMID: 23874839) Stem Cells. 2010 Mar 31;28(3):555-63. (PMID: 20073042) Stem Cell Res Ther. 2019 Aug 5;10(1):235. (PMID: 31383013) Methods Enzymol. 2006;419:337-83. (PMID: 17141062) Mol Ther. 2004 May;9(5):747-56. (PMID: 15120336) Int Rev Cell Mol Biol. 2011;288:185-225. (PMID: 21482413) Stem Cells Transl Med. 2017 Jan;6(1):209-222. (PMID: 28170197) Ann Rheum Dis. 2020 Sep;79(9):1251-1252. (PMID: 32354772) Eur Cytokine Netw. 2020 Sep 1;31(3):81-93. (PMID: 33361013) Cytotherapy. 2006;8(4):315-7. (PMID: 16923606) Int Immunopharmacol. 2021 Aug;97:107694. (PMID: 33932694) Methods Mol Biol. 2021;2286:121-129. (PMID: 33381853) J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193) J Cell Physiol. 2012 Dec;227(12):3756-67. (PMID: 22378492) Front Bioeng Biotechnol. 2019 Nov 15;7:338. (PMID: 31803733) Toxicol In Vitro. 2010 Jun;24(4):1053-63. (PMID: 20362047) Curr Cardiol Rep. 2021 Jul 28;23(9):128. (PMID: 34319478) Altern Lab Anim. 2014 Jun;42(3):207-9. (PMID: 25068932) Methods Enzymol. 2000;322:472-9. (PMID: 10914040) Front Immunol. 2020 May 19;11:1091. (PMID: 32574263) Arthritis Rheum. 2002 Oct;46(10):2794-803. (PMID: 12384940) Cell Biosci. 2020 Jun 3;10:75. (PMID: 32518618) Cancer Res. 2018 Sep 15;78(18):5243-5258. (PMID: 30012670) Curr Opin Hematol. 2006 Nov;13(6):419-25. (PMID: 17053453) Tissue Eng Part C Methods. 2020 May;26(5):263-275. (PMID: 32268824) Immunol Rev. 2018 Jan;281(1):57-61. (PMID: 29247996) Transfusion. 2018 Oct;58(10):2374-2382. (PMID: 30203447) PLoS One. 2015 Jun 24;10(6):e0128973. (PMID: 26107378) Stem Cells. 2021 Jun;39(6):707-722. (PMID: 33586320) Stem Cells. 2007 Aug;25(8):2118-27. (PMID: 17478584) Chem Phys Lipids. 2021 Jan;234:105009. (PMID: 33189639) Immunol Cell Biol. 2006 Oct;84(5):413-21. (PMID: 16869941) Stem Cells Int. 2018 Nov 11;2018:2406462. (PMID: 30534156) Cytotherapy. 2016 Apr;18(4):523-35. (PMID: 26971681) J Transl Med. 2015 Mar 20;13:95. (PMID: 25889845) J Clin Med Res. 2017 Nov;9(11):935-942. (PMID: 29038672) Cancer Lett. 2019 Feb 1;442:271-278. (PMID: 30439540) Histochem Cell Biol. 2010 Jan;133(1):125-34. (PMID: 19830445) Oxid Med Cell Longev. 2016;2016:9346242. (PMID: 27528888) |
| Grant Information: | FF-2019-448, FF-2019-448/1 Ming Medical Sdn. Bhd. |
| Contributed Indexing: | Keywords: Wharton’s jelly mesenchymal stem cells; human platelet lysate; microcarriers; three-dimensional culture; xeno-free culture |
| Substance Nomenclature: | 0 (Culture Media) |
| Entry Date(s): | Date Created: 20230225 Date Completed: 20230323 Latest Revision: 20230323 |
| Update Code: | 20230323 |
| PubMed Central ID: | PMC9960744 |
| DOI: | 10.3390/ijms24043745 |
| PMID: | 36835154 |
| Database: | MEDLINE |
| Full text is not displayed to guests. | Login for full access. |
Accede al texto completo | ISSN: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms24043745 |